Tavilermide

Tavilermide is a pharmaceutical drug that was under development for the treatment of dry eye syndrome. It was developed by Mimetogen Pharmaceuticals, a company based in Montreal, Canada. The drug was designed to stimulate the production of mucin, a key component of the tear film, in the eye's surface cells. However, the development of Tavilermide was discontinued in 2018.

History

Tavilermide was initially developed by Mimetogen Pharmaceuticals, a company that specializes in the development of small molecule drugs. The drug was designed to stimulate the production of mucin in the eye's surface cells, which is a key component of the tear film. This was intended to help alleviate the symptoms of dry eye syndrome.

In 2013, Mimetogen entered into a licensing agreement with Allergan, a global pharmaceutical company, for the development and commercialization of Tavilermide. The drug entered Phase 3 clinical trials in 2015.

However, in 2018, Allergan announced that it was discontinuing the development of Tavilermide. The decision was made following the results of two Phase 3 clinical trials, which showed that the drug did not meet its primary endpoint of improving the signs and symptoms of dry eye syndrome.

Mechanism of Action

Tavilermide is a small molecule that mimics the action of nerve growth factor (NGF). It works by binding to the TrkA receptor, which is found on the surface of cells in the eye. This stimulates the production of mucin, a key component of the tear film that helps to keep the eye moist.

Clinical Trials

Tavilermide entered Phase 3 clinical trials in 2015. The trials were designed to evaluate the safety and efficacy of the drug in patients with dry eye syndrome. However, the results of the trials showed that Tavilermide did not meet its primary endpoint of improving the signs and symptoms of dry eye syndrome.

Discontinuation

In 2018, Allergan announced that it was discontinuing the development of Tavilermide. The decision was made following the results of two Phase 3 clinical trials. The company stated that it would continue to focus on its other ophthalmology products.

See Also

• Dry eye syndrome
• Mimetogen Pharmaceuticals
• Allergan
• Clinical trial
• Pharmaceutical drug

Tavilermide Resources
Latest articles Most recent articles Ongoing trials	Wikipedia